Covalent Binding Mechanism of Furmonertinib and Osimertinib With Human Serum Albumin

The biology and management of non-small cell lung cancer

Herbst, R. S., Morgensztern, D., & Boshoff, C. (2018) · Nature · doi:10.1038/nature25183 · Cited by 4,891 · see citing works

Kinase-targeted cancer therapies: progress, challenges and future directions

Bhullar, K. S., Orrego-Lagarón, N., McGowan, E. M., Parmar, I., Jha, A., Hubbard, B. P., & Rupasinghe, H. P. V. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0804-2 · Cited by 1,260 · see citing works

Osimertinib As First-Line Treatment of EGFR Mutation–Positive Advanced Non–Small-Cell Lung Cancer

Ramalingam, S. S., Yang, J. C., Lee, C. K., Kurata, T., Kim, D., John, T., Nogami, N., Ohe, Y., Mann, H., Rukazenkov, Y., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.7576 · Cited by 554 · see citing works

Managing the challenge of chemically reactive metabolites in drug development

Park, B. K., Boobis, A. R., Clarke, S. E., Goldring, C. E., Jones, D., Kenna, J. G., Lambert, C., Laverty, H., Naisbitt, D. J., Nelson, S. D., et al. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3408 · Cited by 466 · see citing works

Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, EGFR -Mutated Non–Small Cell Lung Cancer

Janne, P. A., Baik, C., Su, W.-C., Johnson, M. L., Hayashi, H., Nishio, M., Kim, D.-W., Koczywas, M., Gold, K. A., Steuer, C. E., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0715 · Cited by 302 · see citing works

PKIDB: A Curated, Annotated and Updated Database of Protein Kinase Inhibitors in Clinical Trials

Carles, F., Bourg, S., Meyer, C., & Bonnet, P. (2018) · Molecules · doi:10.3390/molecules23040908 · Cited by 202 · see citing works

Lysine residue 199 of human serum albumin is modified by acetylsalicylic acid

Walker, J. E. (1976) · FEBS Letters · doi:10.1016/0014-5793(76)80496-6 · Cited by 118 · see citing works

Approved and Experimental Small‐Molecule Oncology Kinase Inhibitor Drugs: A Mid‐2016 Overview

Fischer, P. M. (2016) · Medicinal Research Reviews · doi:10.1002/med.21409 · Cited by 81 · see citing works

Amoxicillin and Clavulanate Form Chemically and Immunologically Distinct Multiple Haptenic Structures in Patients

Meng, X., Earnshaw, C. J., Tailor, A., Jenkins, R. E., Waddington, J. C., Whitaker, P., French, N. S., Naisbitt, D. J., & Park, B. K. (2016) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.6b00253 · Cited by 62 · see citing works

Characterization of HKI-272 Covalent Binding to Human Serum Albumin

Wang, J., Li-Chan, X. X., Atherton, J., Deng, L., Espina, R. J., Yu, L., Horwatt, P., Ross, S. A., Lockhead, S., Ahmad, S. S., et al. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.032292 · Cited by 61 · see citing works

Mass Spectrometric and Functional Aspects of Drug–Protein Conjugation

Tailor, A., Waddington, J. C., Meng, X., & Park, B. K. (2016) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.6b00147 · Cited by 57 · see citing works

β-Lactam Antibiotics Form Distinct Haptenic Structures on Albumin and Activate Drug-Specific T-Lymphocyte Responses in Multiallergic Patients with Cystic Fibrosis

Jenkins, R. E., Yaseen, F. S., Monshi, M. M., Whitaker, P., Meng, X., Farrell, J., Hamlett, J., Sanderson, J. P., El-Ghaiesh, S. H., Peckham, D. G., et al. (2013) · Chemical Research in Toxicology · doi:10.1021/tx400124m · Cited by 56 · see citing works

An oligoclonal antibody durably overcomes resistance of lung cancer to third‐generation EGFR inhibitors

Mancini, M., Gal, H., Gaborit, N., Mazzeo, L., Romaniello, D., Salame, T. M., Lindzen, M., Mahlknecht, G., Enuka, Y., Burton, D. G. A., et al. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201708076 · Cited by 51 · see citing works

Covalent binding of acetaminophen to mouse hemoglobin. Identification of major and minor adducts formed in vivo and implications for the nature of the arylating metabolites

Axworthy, D. B., Hoffmann, K., Streeter, A. J., Calleman, C. J., Pascoe, G. A., & Baillie, T. A. (1988) · Chemico-Biological Interactions · doi:10.1016/0009-2797(88)90009-9 · Cited by 42 · see citing works

Metabolism and disposition of pyrotinib in healthy male volunteers: covalent binding with human plasma protein

Meng, J., Liu, X.-Y., Ma, S., Zhang, H., Yu, S.-D., Zhang, Y.-F., Chen, M.-X., Zhu, X.-Y., Liu, Y., Yi, L., et al. (2019) · Acta Pharmacologica Sinica · doi:10.1038/s41401-018-0176-6 · Cited by 41 · see citing works

Binding of benzyl penicilloyl to human serum albumin Evidence for a highly reactive region at the junction of domains 1 and 2 of the albumin molecule

Yvon, M., Anglade, P., & Wal, J. (1989) · FEBS Letters · doi:10.1016/0014-5793(89)81351-1 · Cited by 40 · see citing works

Metabolite Identification in the Preclinical and Clinical Phase of Drug Development

Wu, Y., Pan, L., Chen, Z., Zheng, Y., Diao, X., & Zhong, D. (2021) · Current Drug Metabolism · doi:10.2174/1389200222666211006104502 · Cited by 39 · see citing works

Osimertinib and anti-HER3 combination therapy engages immune dependent tumor toxicity via STING activation in trans

Vicencio, J. M., Evans, R., Green, R., An, Z., Deng, J., Treacy, C. A., Mustapha, R., Monypenny, J., Costoya, C., Lawler, K., et al. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04701-3 · Cited by 33 · see citing works

Characterization of covalent binding of tyrosine kinase inhibitors to plasma proteins

Liu, X., Feng, D., Zheng, M., Cui, Y., & Zhong, D. (2020) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2020.07.002 · Cited by 32 · see citing works

Metabolic disposition of the EGFR covalent inhibitor furmonertinib in humans

Meng, J., Zhang, H., Bao, J.-J., Chen, Z.-D., Liu, X.-Y., Zhang, Y.-F., Jiang, Y., Miao, L.-Y., & Zhong, D.-F. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-021-00667-8 · Cited by 23 · see citing works

Quantification of Osimertinib and Metabolite–Protein Modification Reveals Its High Potency and Long Duration of Effects on Target Organs

Gong, S., Zhuo, Y., Chen, S., Hu, X., Fan, X., Wu, J., & Li, N. (2021) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.1c00195 · Cited by 9 · see citing works

Lysine reactivity profiling reveals molecular insights into human serum albumin–small-molecule drug interactions

Yang, S., Zhang, W., Liu, Z., Zhai, Z., Hou, X.-D., Wang, P., Ge, G., & Wang, F. (2021) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-021-03700-1 · Cited by 9 · see citing works

Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials

Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396 · see citing works

Emerging and Re-emerging Warheads for Targeted Covalent Inhibitors: An Update

Hillebrand, L., Liang, X. J., Serafim, R. A. M., & Gehringer, M. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01825 · Cited by 212 · see citing works

Optimizing Osimertinib for NSCLC: Targeting Resistance and Exploring Combination Therapeutics

Liao, Y.-Y., Tsai, C.-L., & Huang, H. (2025) · Cancers · doi:10.3390/cancers17030459 · Cited by 28 · see citing works

Oxidative Stress in Antigen Processing and Presentation

Chang, Q., Zhang, Y., Liu, X., Miao, P., Pu, W., Liu, S., Zhang, J., Yuan, T., Shen, G., & Xie, N. (2025) · MedComm – Oncology · doi:10.1002/mog2.70020 · Cited by 21 · see citing works

Binding Investigation of Some Important Metal Ions Copper (I), Nickel (II), and Aluminium (III) with Bovine Serum Albumin Using Valid Spectroscopic Techniques

Alhazmi, H. A., Alam, M. S., Albratty, M., Najmi, A., Abdulhaq, A. A., Hassani, R., Ahsan, W., & Qramish, A. N. (2023) · Journal of Chemistry · doi:10.1155/2023/2581653 · Cited by 20 · see citing works

Physiologically Based Pharmacokinetic Model of Tyrosine Kinase Inhibitors to Predict Target Site Penetration, with PET ‐Guided Verification

van der Gaag, S., Jordens, T., Yaqub, M. M., Grijseels, R., van Valkengoed, D. W., de Langen, E. N., van den Broek, R., Thijssen, V. L., Langen, A. J. D., Kouwenhoven, M. C. M., et al. (2025) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.70006 · Cited by 16 · see citing works

The hemostatic molecular mechanism of Sanguisorbae Radix's pharmacological active components based on HSA: Spectroscopic investigations, molecular docking and dynamics simulation

Xu, F., Shen, Y., Pan, Z., Zhou, X., Gu, W., Dong, J., Yin, S., Liu, S., Xu, M., & Chen, B. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e37020 · Cited by 11 · see citing works

The Relationship Between Efficacy and Safety of Osimertinib Blood Concentration in Patients With EGFR Mutation-positive Lung Cancer: A Prospective Observational Study

Hashino, Y., Hatsuyama, T., Iwayama, K., HOSHI, T., Wakamoto, A., Ohtaki, K., Toda, T., & Sato, H. (2023) · In Vivo · doi:10.21873/invivo.13376 · Cited by 10 · see citing works

In vitro metabolism of targeted covalent inhibitors and their thiol conjugates by gut microbiome from rats, mice, and humans

Gu, T., Cai, J., Auster, A., Torres, E., Zhang, D., Khojasteh, S. C., & Wang, S. (2024) · Drug Metabolism and Disposition · doi:10.1016/j.dmd.2024.100027 · Cited by 9 · see citing works

Biotransformation research advances – 2022 year in review

Khojasteh, S. C., Argikar, U. A., Cheruzel, L., Cho, S., Crouch, R. D., Dhaware, D., Heck, C. J. S., Johnson, K. M., Kalgutkar, A. S. S., King, L. M., et al. (2023) · Drug Metabolism Reviews · doi:10.1080/03602532.2023.2262161 · Cited by 6 · see citing works

The function of albumin and its application in tumor therapy

Xu, T., Na, J., Liu, Q., Kuang, G., Zhang, Q., & Zhao, Y. (2024) · Materials Today Communications · doi:10.1016/j.mtcomm.2024.110575 · Cited by 5 · see citing works

Albumin as a Drug Delivery System: Mechanisms, Applications, and Innovations

Al-Harthi, S., Alshehri, A., Alhudhali, L., Alghrably, M., Bennici, G., Almohaywi, M., Jaremko, Ł., & Jaremko, M. (2025) · IntechOpen eBooks · doi:10.5772/intechopen.1011323 · Cited by 4 · see citing works

Pharmacokinetics, mass balance, and metabolism of [14C]PLB1004, a selective and irreversible EGFR-TKI in humans

Liu, D., Li, Q., Yan, S., Zhang, X., Li, W., Wang, F., Gao, L., Geng, F., Zhou, H., Ye, P., et al. (2025) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-024-04744-7 · Cited by 2 · see citing works

Tumor-Targeted Delivery of an EGFR Inhibitor Prodrug via Site-Specific Albumin Conjugation

Federa, A., Pitek, R., Dömötör, O., Enyedy, É. A., Terenzi, A., Caban, M., Stefanelli, A., D’Anna, L., White, F., Heffeter, P., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02536 · Cited by 2 · see citing works

Covalent Radiopharmaceuticals: Precision Imaging and Therapy for Cancer

Klauser, P. C., & Wang, L. (2026) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c01912 · Cited by 2 · see citing works

Search for Possible Conjugation Sites of Electrophiles with Biomolecules by Molecular Modeling

Belinskaia, D. A., & Savelieva, E. I. (2025) · Russian Journal of Bioorganic Chemistry · doi:10.1134/s1068162025601211

Development and Verification of a Physiologically Based Pharmacokinetic Model of Furmonertinib and Its Main Metabolite for Drug–Drug Interaction Predictions

Wu, Y., Loer, H. L. H., Zhang, Y., Zhong, D., Jiang, Y., Hu, J., Fuhr, U., Lehr, T., & Diao, X. (2025) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.70052

Bovine Colostrum-Derived Lactoferrin Nanoparticles as a Novel Platform for Improved Pulmonary Delivery of Osimertinib

Abbas, Z. S., Nasif, Z. N., & Tawfeeq, A. T. (2025) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-025-01931-y

Generation and characterization of a serum albumin-humanized mouse model and its utility for detection of albumin adduct formation in vivo

Wu, X., Han, W., Yin, L., Yang, W., Sheng, J. J., Han, J., Turesky, R. J., Winkle, L. S. V., Zhang, Q.-Y., & Ding, X. (2026) · Drug Metabolism and Disposition · doi:10.1016/j.dmd.2026.100354

BindingDB Entry 50021193: Emerging and Re-emerging Warheads for Targeted Covalent Inhibitors: An Update.

BindingDB (2025) · UC San Diego · doi:10.7270/q2vm4hvh

Characterization of covalent binding of tyrosine kinase inhibitors to plasma proteins

Liu, X., Feng, D., Zheng, M., Cui, Y., & Zhong, D. (2020) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2020.07.002 · Cited by 32 · see citing works

225P The potential synergistic mechanism of the combination of osimertinib and furmonertinib (3+3 mode): Evidence from an in vitro experimental study and structural modeling

Liang, W., Chen, Z., & Liu, X. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.102865

Reversible Covalent Binding of Neratinib to Human Serum Albumin In Vitro

Chandrasekaran, A., Shen, L., Lockhead, S., Oganesian, A., Wang, J., & Scatina, J. (2010) · Drug Metabolism Letters · doi:10.2174/187231210792928206 · Cited by 40 · see citing works

Binding mechanism of the tyrosine-kinase inhibitor nilotinib to human serum albumin determined by 1 H STD NMR, 19 F NMR, and molecular modeling

Yan, J., Wu, D., Sun, P., Ma, X., Wang, L., Li, S., Xu, K., & Li, H. (2016) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2016.02.024 · Cited by 19 · see citing works

Insight into the Therapeutic Selectivity of the Irreversible EGFR Tyrosine Kinase Inhibitor Osimertinib through Enzyme Kinetic Studies

Zhai, X., Ward, R. A., Doig, P. C., & Argyrou, A. (2020) · Biochemistry · doi:10.1021/acs.biochem.0c00104 · Cited by 83 · see citing works